JP2021514948A5 - - Google Patents

Info

Publication number
JP2021514948A5
JP2021514948A5 JP2020544019A JP2020544019A JP2021514948A5 JP 2021514948 A5 JP2021514948 A5 JP 2021514948A5 JP 2020544019 A JP2020544019 A JP 2020544019A JP 2020544019 A JP2020544019 A JP 2020544019A JP 2021514948 A5 JP2021514948 A5 JP 2021514948A5
Authority
JP
Japan
Prior art keywords
average molecular
molecular weight
powder
nanoparticles
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020544019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514948A (ja
JP7416430B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2019/050217 external-priority patent/WO2019162951A1/en
Publication of JP2021514948A publication Critical patent/JP2021514948A/ja
Publication of JP2021514948A5 publication Critical patent/JP2021514948A5/ja
Application granted granted Critical
Publication of JP7416430B2 publication Critical patent/JP7416430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544019A 2018-02-26 2019-02-26 薬物送達システム Active JP7416430B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862635088P 2018-02-26 2018-02-26
US62/635,088 2018-02-26
PCT/IL2019/050217 WO2019162951A1 (en) 2018-02-26 2019-02-26 Drug delivery systems

Publications (3)

Publication Number Publication Date
JP2021514948A JP2021514948A (ja) 2021-06-17
JP2021514948A5 true JP2021514948A5 (enExample) 2022-03-09
JP7416430B2 JP7416430B2 (ja) 2024-01-17

Family

ID=65763696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544019A Active JP7416430B2 (ja) 2018-02-26 2019-02-26 薬物送達システム

Country Status (9)

Country Link
US (1) US20210128534A1 (enExample)
EP (1) EP3758677A1 (enExample)
JP (1) JP7416430B2 (enExample)
KR (2) KR102717886B1 (enExample)
CN (1) CN112004524B (enExample)
AU (1) AU2019226051B2 (enExample)
CA (1) CA3092016A1 (enExample)
IL (1) IL276784B2 (enExample)
WO (1) WO2019162951A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
BR112015027291A8 (pt) 2013-05-03 2019-12-24 Selecta Biosciences Inc uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
WO2016037164A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
KR102753928B1 (ko) 2017-03-11 2025-01-14 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
GB201810925D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and methods of treatment
GB201810923D0 (en) * 2018-07-03 2018-08-15 Blueberry Therapeutics Ltd Compositions and method of treatment
EP3980784A1 (en) 2019-06-04 2022-04-13 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
BR112022010952A2 (pt) * 2019-12-05 2022-09-06 West Virginia Univ Board Of Governors On Behalf Of West Virginia Univ Nanosferas de plga carregadas de proteína
AU2021236234A1 (en) * 2020-03-11 2022-10-06 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers
EP4167979A1 (en) * 2020-06-19 2023-04-26 Cannovex BV Pulmonary formulation comprising cannabinoids
KR20230047095A (ko) 2020-07-29 2023-04-06 카낙 테크놀로지스, 엘엘씨 치료용 친유성 활성물질의 개선된 전달을 위한 약제학적 조성물
CA3166084C (en) 2020-07-29 2025-06-10 Karnak Technologies, Llc Oral compositions of beneficial lipophilic, nutriceutical, and edible oil food supplements
EP4199906A1 (en) * 2020-08-20 2023-06-28 Bionanosim (BNS) Ltd Lipid delivery systems for delivery of oxaliplatin palmitate acetate
DK202070707A1 (en) 2020-10-26 2022-05-02 Jacob Holm & Sons Ag Dry CBD Delivery Fabric
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4851067B2 (ja) * 2004-01-28 2012-01-11 ホソカワミクロン株式会社 ナノ粒子含有組成物およびその製造方法
EP1655021B1 (en) * 2004-11-09 2008-10-29 Novagali Pharma SA Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
KR101319772B1 (ko) * 2004-11-09 2013-10-23 노바갈리 파르마 에스 에이 면역 억제제를 포함하는 안과용 유제
CN1903365A (zh) * 2005-07-28 2007-01-31 中国医学科学院生物医学工程研究所 载药纳米微粒及其制备方法和该微粒在制备抗血管再狭窄制剂中的应用
ES2425969T3 (es) * 2007-04-27 2013-10-18 Kyushu University, National University Corporation Agente para el tratamiento de enfermedades pulmonares
CN101810563B (zh) * 2009-09-25 2012-04-25 宋洪涛 他克莫司眼用在体凝胶制剂及其制备方法
US20140079642A1 (en) * 2011-01-24 2014-03-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nanoparticles based for dermal and systemic delivery of drugs
US20170065533A1 (en) * 2011-01-24 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles for dermal and systemic delivery of drugs
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
US9724304B2 (en) * 2012-06-14 2017-08-08 Temple University—Of the Commonwealth System of Higher Education Nanospheres for therapeutic agent delivery
CN102772827B (zh) * 2012-07-13 2014-05-07 华南理工大学 Plga/羟基磷灰石/碳酸钙复合微球及其制备方法
KR101940888B1 (ko) * 2013-12-31 2019-01-21 피비앤비 에스에이 체형 복원 및 체형 관리용 제어 방출 지방산 조성물
EP3154524B1 (en) * 2014-06-12 2021-12-15 Adare Pharmaceuticals USA, Inc. Extended-release drug delivery compositions
GB201419540D0 (en) * 2014-11-03 2014-12-17 Nanomerics Ltd Delivery of drugs
CN105769821B (zh) * 2016-04-19 2019-06-14 浙江工业大学 他克莫司自组装聚合物纳米粒给药系统及其制备方法

Similar Documents

Publication Publication Date Title
Sanna et al. Polymeric nanoparticles encapsulating white tea extract for nutraceutical application
Ong et al. Chitosan-propolis nanoparticle formulation demonstrates anti-bacterial activity against Enterococcus faecalis biofilms
Adlravan et al. Potential activity of free and PLGA/PEG nanoencapsulated nasturtium officinale extract in inducing cytotoxicity and apoptosis in human lung carcinoma A549 cells
Li et al. Anti-tumor activity of paclitaxel-loaded chitosan nanoparticles: An in vitro study
Cosco et al. Rutin-loaded chitosan microspheres: Characterization and evaluation of the anti-inflammatory activity
Nathiya et al. Quercetin, encapsulated quercetin and its application—A review
Wang et al. Nanoceria‐loaded injectable hydrogels for potential age‐related macular degeneration treatment
Popat et al. Curcumin-cyclodextrin encapsulated chitosan nanoconjugates with enhanced solubility and cell cytotoxicity
Mobahat et al. Curcumin-loaded human endometrial stem cells derived exosomes as an effective carrier to suppress alpha-synuclein aggregates in 6OHDA-induced Parkinson’s disease mouse model
Matokanovic et al. Hsp70 silencing with siRNA in nanocarriers enhances cancer cell death induced by the inhibitor of Hsp90
Khatoon et al. Nanoencapsulation of polyphenols as drugs and supplements for enhancing therapeutic profile-a review
Wahab et al. Nanomaterials for the delivery of Herbal Bioactive Compounds
Kustiawan et al. New insights of propolis nanoformulation and its therapeutic potential in human diseases
Karavelioglu et al. Preparation of chitosan nanoparticles as Ginkgo Biloba extract carrier: In vitro neuroprotective effect on oxidative stress-induced human neuroblastoma cells (SH-SY5Y)
Özakar et al. A comprehensive study on peppermint oil and cinnamon oil as nanoemulsion: preparation, stability, cytotoxicity, antimicrobial, antifungal, and antioxidant activity
Nguyen et al. Chitosan/cyclodextrin surface-adsorbed naringenin-loaded nanocapsules enhance bacterial quorum quenching and anti-biofilm activities
Hoyos-Ceballos et al. Design of epigallocatechin gallate loaded PLGA/PF127 nanoparticles and their effect upon an oxidative stress model
Alamoudi et al. Chitosan/hesperidin nanoparticles formulation: a promising approach against ethanol-induced gastric ulcers via Sirt1/FOXO1/PGC-1α/HO-1 pathway
El-Sherbiny et al. Fabrication and assessment of potent anticancer nanoconjugates from chitosan nanoparticles, curcumin, and eugenol
Villate et al. Development, characterization and in vitro gastrointestinal release of PLGA nanoparticles loaded with full-spectrum cannabis extracts
Al Rashid Preparation and characterization of PLGA loaded nanoparticles obtained from D. melanoxylon Roxb. leaves for their antiproliferative and antidiabetic activity
Bona et al. Antitumoral activity of Cecropia pachystachya leaves extract in vitro and in vivo model of rat glioma: Brain and blood effects
Quiroz-Reyes et al. Development and characterization of gelatin nanoparticlesloaded with a cocoa-derived polyphenolic extract
García-López et al. Zebrafish, a model to develop nanotherapeutics that control neutrophils response during inflammation
Mishra et al. A review of various pharmacological effects of quercetin with its barriers and approaches for solubility and permeability enhancement